Clinical trials
Blood Disease clinical trials
Below are recruiting blood disease clinical trials, each written for real people, not researchers. We’re tracking 634 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06608732RecruitingPhase 2
CAR-T therapy plus stem cell transplant for B-cell ALL with MRD
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
Tianjin, Tianjin MunicipalityAges 16–70 - NCT06613880RecruitingPhase 2
Romiplostim with standard therapy for severe aplastic anemia
This trial tests combining a drug called romiplostim (a bone marrow stimulant) with standard immunosuppressive therapy as a first treatment for severe aplastic anemia. It aims to improve blood cell counts and reduce the need for transfusions.
Tianjin, Tianjin MunicipalityAges 12 years+ - NCT06622694RecruitingPhase 1
CD7 car-t cells for severe aplastic anemia
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06635681RecruitingPhase 2
Venetoclax plus intensive chemo for AML subtypes
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT06658834RecruitingPhase 2
Romiplostim for newly diagnosed ITP in adults
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06689410Recruiting
Brain aneurysm research registry and biobank
This study is collecting medical information and samples from people with brain aneurysms to learn more about the condition. If you have a recently found aneurysm, you may be able to help researchers understand how aneurysms form and how to better treat them in the future.
Nantes, Loire-AtlantiqueAges 18 years+ - NCT06695741RecruitingPhase 2
Lower dose cyclophosphamide with standard therapy for severe aplastic anemia
This trial tests a lower dose of the chemotherapy drug cyclophosphamide combined with standard immune-suppressing medicines for people with newly diagnosed severe aplastic anemia. The goal is to see if this approach works as well as the usual treatment but with fewer side effects.
Tianjin, Tianjin MunicipalityAges 12 years+ - NCT06716658RecruitingPhase 2
New targeted drug for certain T/NK-cell lymphomas
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06733610RecruitingPhase 1
CAR T-cell therapy for AIHA after 3 failed treatments
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06776510RecruitingPhase 1/Phase 2
NAD for immune thrombocytopenia study
This trial tests if a substance called NAD can help adults with immune thrombocytopenia (ITP) whose platelet levels stay low even after standard treatments. ITP is a condition where the immune system attacks platelets, causing easy bruising and bleeding. The study aims to see if NAD can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06783790RecruitingPhase 2
Avapritinib combo for relapsed AML after transplant
This trial tests a combination of three drugs (avapritinib, azacitidine, and venetoclax) for people whose acute myeloid leukemia (AML) has returned after a stem cell transplant. It targets a specific genetic change (C-KIT mutation) to try to stop the cancer from growing.
TianjinAges 18 years+ - NCT06793449RecruitingPhase 2
BCMA CAR-T vs. stem cell transplant for multiple myeloma
This trial tests whether a newer immune treatment (BCMA CAR-T) works better than a stem cell transplant for people with multiple myeloma who are able to have a transplant. Both treatments aim to kill myeloma cells, but CAR-T uses your own engineered immune cells.
TianjinAges 18–70 - NCT06799611RecruitingPhase 2
CM336 for immune thrombocytopenia (ITP)
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06838962RecruitingPhase 2
Study of anti-CD38 antibody for children with chronic ITP
This trial tests a new antibody treatment (anti-CD38) for children ages 6 to 18 who have had low platelets for at least 3 months and did not improve with steroids. The goal is to see if this treatment can safely raise platelet counts.
Tianjin, Tianjin MunicipalityAges 6–18 - NCT06855810RecruitingPhase 2/Phase 3
New treatment study for children with T-cell ALL
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
Hefei, AnhuiAges 1 month–18 years - NCT06880354RecruitingPhase 1
Dual-target CAR-T cells for relapsed or refractory AML
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
TianjinAges 18–70 - NCT06880393RecruitingPhase 2
BCMA CAR-T for high-risk multiple myeloma
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
TianjinAges 18–75 - NCT06882057RecruitingPhase 2/Phase 3
Treatment for newly diagnosed low-risk pediatric B-ALL
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
Hefei, AnhuiAges 1–18 - NCT06918834RecruitingPhase 2
Immediate vs bridging transplant for high-risk MDS
This trial compares getting a stem cell transplant right away versus getting other treatments first before transplant for people with high-risk myelodysplastic syndrome (MDS), a bone marrow disorder. It aims to see which approach leads to better outcomes.
Beijin, Beijing MunicipalityAges 18 years+ - NCT06921980Recruiting
Cell therapy and brain function in AIHA
This trial looks at how cell therapy may affect your brain function and mood if you have autoimmune hemolytic anemia. It aims to help doctors understand the psychological changes that can happen during treatment.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06936930Recruiting
Reproductive and Mental Health in Aplastic Anemia
This study looks at how aplastic anemia affects reproductive and mental health in adults. By understanding these connections, doctors can provide better support for your overall well-being.
Tianjin, Tianjin MunicipalityAges 18–40 - NCT06988059RecruitingEarly Phase 1
Car T-cell therapy for plasma cell leukemia
This trial tests a new Car T-cell treatment called CT0596 for patients with plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this therapy can help control the disease in patients who have already tried other treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06992128RecruitingPhase 2
Romiplostim plus steroids for newly diagnosed ITP
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06992076Recruiting
Hemophilia patients' experience with marstacimab treatment
This registry study follows people with hemophilia A or B who are taking marstacimab as their regular preventive treatment. It aims to understand how the medicine works in real life and how patients feel during treatment.
Xiamen, FujianAges 12 years+
Hear when a new Blood Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for blood disease?
- Yes. Clin2 currently lists 634 recruiting blood disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a blood disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a blood disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.